GlucoLight's OCGM Non-Invasive Blood Glucose Monitor In Clinical Trials.

This press release is an announcement submitted by GREGORY | FCA on behalf of GlucoLight, and was not written by Diabetes Health.

Apr 18, 2007

GlucoLight's continuous, non-invasive device is a novel approach to glucose monitoring in the acute care environment.  Using optical coherence tomography (OCT), the device is able to measure blood glucose levels through a unique anatomical area in the skin that shows physiological changes that directly correlate to changes in blood glucose.  The GlucoLight monitor displays real time glucose measurements with an initial single point calibration.

Mr. Krauss continued, "We have developed and demonstrated a device that will provide physicians and health care workers with a product that not only provides continuous data, but will help offset labor and supply costs for hospitals.  In recent trials, we have been extremely pleased with the device's accuracy."

Blood glucose monitoring has been called "the next vital sign", linking elevated levels with complications for all patients following surgery.  Intensive glucose control protocols, including the "Portland Protocol" developed by Dr. Tony Furnary, have been shown to decrease mortality and morbidity and reduce infections in post cardiac surgery patients.

GlucoLight's OCGM device is intended to provide an efficient method to monitor patients' glucose levels in real-time, effectively reducing the time spent on traditional blood testing methods and making it easier to achieve the cost savings associated with intensive glucose control, estimated to be $2,800 per patient.

Mr. Krauss concluded, "Based on compelling data that reinforces the importance of tight glycemic control in the acute care environment, coupled with the worldwide diabetes epidemic, we estimate the size of our near-term addressable market to be at least $500 million. In the coming months, our efforts will focus on additional product refinements to our device for the acute care environment and for eventual FDA evaluation.  Eventually, we will miniaturize our glucose monitoring technology and develop a consumer product that will help both Type I and Type II diabetics better manage their glucose levels, and help decrease the complications associated with this world-wide illness."

Medical Capital Advisors of Boston, MA serves as financial advisor to GlucoLight.  The GlucoLight OCGM monitor requires regulatory clearance and is not yet commercially available.

About GlucoLight Corporation: in 2003, GlucoLight is a development-stage company focused on continuous, non-invasive blood glucose monitoring in the acute care environment.

Using Optical Coherence Tomography (OCT), GlucoLight has identified specific physiological targets within the dermis that closely correlate to changes in blood glucose levels.  GlucoLight's OCGM monitor samples these physiological targets every 30 seconds to track blood glucose levels to a high degree of accuracy.

Today, GlucoLight's OCGM monitor is the only continuous, non-invasive blood glucose monitor for the acute care environment that is in clinical trials.

For more information, visit

Press Release Submitted by:
Kristen Forbriger
27 West Athens Avenue, Ardmore, PA 19003
Check out our new website at

Click Here To View Or Post Comments

Categories: Blood Glucose, CGMs, Diabetes, Diabetes, Hospital Care, Noninvasive Monitors, Professional Issues, Type 1 Issues

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.